DDInter608 DDInter899
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Duloxetine {u} (Compound) resembles {v} (Compound) Atomoxetine
Duloxetine {u} (Compound) binds {v} (Gene) CYP1A2
Duloxetine {u} (Compound) upregulates {v} (Gene) HMOX1
Duloxetine {u} (Compound) palliates {v} (Disease) bipolar disorder
Duloxetine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Duloxetine {u} (Compound) downregulates {v} (Gene) CDCA4
Duloxetine {u} (Compound) causes {v} (Side Effect) Acute liver injury
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Duloxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pantoprazole
Duloxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ioflupane I-123
Duloxetine (Compound) resembles Atomoxetine (Compound)
Duloxetine (Compound) binds CYP1A2 (Gene)
Duloxetine (Compound) upregulates HMOX1 (Gene)
Duloxetine (Compound) palliates bipolar disorder (Disease)
Duloxetine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Duloxetine (Compound) downregulates CDCA4 (Gene)
Duloxetine (Compound) causes Acute liver injury (Side Effect)
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Pantoprazole
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ioflupane I-123